PDS Biotechnology Corporation (PDSB) Stock

PDS Biotechnology Corporation, based in Florham Park, New Jersey, is a dynamic clinical-stage biopharmaceutical company specializing in the development of advanced cancer immunotherapies. Founded in 2005, PDS Biotechnology is dedicated to pioneering multifunctional treatments aimed at combatting various cancers and infectious diseases.

At the forefront of its portfolio is PDS0101 (HPV16), the company's lead product candidate currently in Phase II clinical trials. This innovative therapy targets recurrent/metastatic head and neck cancer, human papillomavirus (HPV) associated malignancies, and cervical cancer, offering promising new treatment options in these challenging indications.

In addition to PDS0101, PDS Biotechnology is advancing several other product candidates through preclinical trials. These include PDS0102 (TARP) for prostate and breast cancers, PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers, and PDS0104 (Tyrosinase-related protein 2) for melanoma treatment. The company's diverse pipeline also encompasses PDS0201 for tuberculosis, PDS0202 as an influenza vaccine candidate, and PDS0203 for COVID-19 prevention, reflecting its broad-ranging commitment to addressing critical global health challenges.

Through strategic partnerships and license agreements with prestigious entities such as the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH, PDS Biotechnology accelerates its research and development efforts. By leveraging cutting-edge immunotherapy approaches and innovative collaborations, PDS Biotechnology aims to transform the landscape of cancer treatment and infectious disease prevention, offering hope to patients worldwide.